Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Descartes-25 · DC-25

Cell therapy (Stem-cell derived) · developed by Cartesian Therapeutics

Phase 1 Most advanced trial (none active)

RNAC Developer

1 Registered trials

What is Descartes-25?

Descartes-25 (DC-25) is an allogeneic mesenchymal stem cell product studied in multiple myeloma and relapsed multiple myeloma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: DC-25
Drug type: Cell therapy (Stem-cell derived)
Therapy area: Oncology
Developer: Cartesian Therapeutics (RNAC)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT05113342	Phase 1	Multiple Myeloma	Terminated	RNAC

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Multiple MyelomaRelapse Multiple Myeloma

More from Cartesian Therapeutics

Descartes 30 Phase 1 Descartes-08 Phase 3 Descartes-11 Phase 2 Descartes-15 Phase 1

Sources

ClinicalTrials.gov NCT05113342

Updated Oct 3, 2026. Something wrong or missing? Report it on the RNAC page.

Follow RNAC, the company behind Descartes-25

See RNAC's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

RNAC catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z